Current Treatment Options in Neurology

, Volume 13, Issue 1, pp 15–27 | Cite as

Symptomatic Treatment of Migraine: When to Use NSAIDs, Triptans, or Opiates

Headache

Opinion statement

Migraine is a biologic disorder of the brain characterized by a heterogeneous array of symptoms and episodes of disabling headache. By definition, such attacks last between 4 and 72 h without treatment, with the disability arising from a variety of factors including severe pain, gastrointestinal symptoms such as nausea or vomiting, and sensory sensitivities to light, noise, or odor. All these features may be exacerbated by stimulation, motion, or activity, often rendering the patient completely immobile. Although retreat and rest, coupled with local application of ice, may provide some measure of comfort, most of those with migraine hunt for therapeutic solutions. In designing acute headache treatment strategies, it is imperative for clinicians to recognize the variability between individuals in the frequency, intensity, and duration of attacks. Certain patients require more aggressive options. It is also crucial to identify the significant intra-individual variability of migraine; most patients describe an assortment of headaches of different intensities and time to disability. Less intense episodes, which patients often term sinus, tension, or regular headaches, usually represent milder versions of migraine, simplifying both diagnostic and therapeutic approaches. Evidence-based guidelines and clinical experience support the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of mild to moderate migraine attacks. Recommend migraine-specific agents (triptans and dihydroergotamine) when the attacks are more severe or have consistently failed to respond to the use of NSAIDs in the past. Encourage those with less frequent episodic migraine to use their acute agents at the earliest signs of headache. Advise those with frequent headache (>10 days per month) to limit acute treatments to only the most disabling episodes in order to avoid the “medication overuse” phenomenon. Consider rescue or back-up therapy. Do not use compounds containing butalbital or opiates (or place extreme limits on them), out of concern for progression to chronic migraine.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Charles A, Brennan KC: The neurobiology of migraine. Handb Clin Neurol 2010, 97:99–108. CrossRefPubMedGoogle Scholar
  2. 2.
    Goadsby PJ: Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 2007, 13:39–44.CrossRefPubMedGoogle Scholar
  3. 3.
    Noseda R, Kainz V, Jakubowski M, et al.: A neural mechanism for exacerbation of headache by light. Nature Neuroscience 2010, 13:239–245.CrossRefPubMedGoogle Scholar
  4. 4.
    Levy D, Burstein R, Strassman AM: Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005, 58:698–705.CrossRefPubMedGoogle Scholar
  5. 5.
    Zhang XC, Strassman AM, Burstein R, Levy D: Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J Pharmacol Exp Ther 2007, 322:806–812.CrossRefPubMedGoogle Scholar
  6. 6.
    • Burstein R, Jakubowski M: Managing migraine associated with sensitization. Handb Clin Neurol 2010, 97:207–215. CrossRefPubMedGoogle Scholar
  7. 7.
    Petersen KA, Birk S, Lassen LH, et al.: The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2005, 25:139–147.CrossRefPubMedGoogle Scholar
  8. 8.
    Maizels M, Burchette R: Rapid and sensitive paradigm for screening patients with headache in primary care settings. Headache 2003, 43:441–50.CrossRefPubMedGoogle Scholar
  9. 9.
    Dowson AJ, Lipscombe S, Sender J, et al.: New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002, 18:414–39.CrossRefPubMedGoogle Scholar
  10. 10.
    Cady RK, Freitag FG, Mathew NT, et al.: Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention. Headache 2009, 49:350–363.CrossRefPubMedGoogle Scholar
  11. 11.
    Diener HC, Dodick DW, Goadsby PJ, et al.: Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalalgia 2008, 28:35–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Snow V, Weiss K, Wall E, Mottur-Pilson C: American Academy of Family Physicians; American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Int Med 2002, 137:840–852.PubMedGoogle Scholar
  13. 13.
    Silberstein SD: Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 55:754–62 [Erratum, Neurology 2000;56:142.].PubMedGoogle Scholar
  14. 14.
    • Loder E: Triptan Therapy in migraine. N Engl J Med 2010, 363:63–70.CrossRefPubMedGoogle Scholar
  15. 15.
    Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD: The triptan formulations: how to match patients and products. CNS Drugs 2003, 17:431–447.CrossRefPubMedGoogle Scholar
  16. 16.
    • Taylor FR: Acute treatment of migraine headaches. Semin Neurol 2010, 30:145–153. CrossRefPubMedGoogle Scholar
  17. 17.
    Levy D, Jakubowski M, Burstein R: Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci USA 2004, 101:4274–4279.CrossRefPubMedGoogle Scholar
  18. 18.
    Shields KG, Goadsby PJ: Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis 2006, 23:491–501.CrossRefPubMedGoogle Scholar
  19. 19.
    Bartsch T, Knight YE, Goadsby PJ: Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol 2004, 56:371–381.CrossRefPubMedGoogle Scholar
  20. 20.
    Dodick D, Lipton RB, Martin V, et al.: Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004, 44:414–425.CrossRefPubMedGoogle Scholar
  21. 21.
    •• Evans RW, Tepper SJ, Shapiro RE et al.: The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache 2010, 50:1089–1099. CrossRefPubMedGoogle Scholar
  22. 22.
    Diamond S, Bigal ME, Silberstein S, et al.: Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American migraine prevalence and prevention study. Headache 2007, 47:355–363.PubMedGoogle Scholar
  23. 23.
    Whyte C, Tepper SJ, Evans RW: Expert Opinion: Rescue Me: Rescue Medication for Migraine. Headache 2010, 50:307–313.CrossRefPubMedGoogle Scholar
  24. 24.
    Landy S: Migraine throughout the life cycle. Treatment through the ages. Neurology 2004, 62(Suppl2):S2–S8.PubMedGoogle Scholar
  25. 25.
    Lipton RB, Grosberg B, Singer RP, et al.: Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: Results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia 2010, 30:1336–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Limmroth V, Katsarava Z, Diener HC: Acetylsalicylic acid in the treatment of headache. Cephalalgia 1999, 19:545–551.CrossRefPubMedGoogle Scholar
  27. 27.
    Suthisisang CC, Poolsup N, Suksomboon N, et al.: Meta-Analysis of the Efficacy and Safety of Naproxen Sodium in the Acute Treatment of Migraine. Headache 2010, 50:808–818.CrossRefPubMedGoogle Scholar
  28. 28.
    Lipton RB, Goldstein J, Baggish JS, et al.: Aspirin is efficacious for the treatment of acute migraine. Headache 2005, 45:283–292.CrossRefPubMedGoogle Scholar
  29. 29.
    Lampl C, Voelker M, Diener HC: Efficacy and safety of 1000 mg effervescent aspirin: Individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007, 254:705–712.CrossRefPubMedGoogle Scholar
  30. 30.
    Boureau F, Joubert JM, Lasserre V, et al.: Double-blind comparison of an acetaminophen 400 mg–codeine 25 mg combination versus aspirin 1000 mg and placebo in an acute migraine attack. Cephalalgia 1994, 14:156–161.CrossRefPubMedGoogle Scholar
  31. 31.
    Volans GN: The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol 1975, 2:57–63.PubMedGoogle Scholar
  32. 32.
    Tfelt-Hansen P, Olesen J: Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: A doubleblind study. Cephalalgia 1984, 4:107–111.CrossRefPubMedGoogle Scholar
  33. 33.
    Suthisisang C, Poolsup N, Kittikulsuth W, et al.: Efficacy of low-dose ibuprofen in acute migraine treatment: Systematic review and meta-analysis. Ann Pharmacother 2007, 41:1782–1791.CrossRefPubMedGoogle Scholar
  34. 34.
    Codispoti JR, Prior MJ, Fu M, et al.: Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache 2001, 41:665–679.CrossRefPubMedGoogle Scholar
  35. 35.
    Myllylä VV, Havanka H, Herrala L, et al.: Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: Comparable effect in a double-blind, randomized, controlled, parallel group study. Headache 1998, 38:201–207.CrossRefPubMedGoogle Scholar
  36. 36.
    Tokola RA, Kangasniemi P, Neuvonen PJ, Tokola O: Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks. Cephalalgia 1984, 4:253–263.CrossRefPubMedGoogle Scholar
  37. 37.
    Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M: Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by survivin protein expression. Mol Cancer Ther 2009, 8:533–542.CrossRefPubMedGoogle Scholar
  38. 38.
    The Diclofenac-K/Sumatriptan Migraine Study Group: Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 1999, 19:232–240.CrossRefGoogle Scholar
  39. 39.
    Dahlof C, Bjorkman R: Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993, 13:117–123.CrossRefPubMedGoogle Scholar
  40. 40.
    Peroutka SJ, Lyon JA, Swarbrick J, et al.: Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: a randomized, double-blind, crossover study. Headache 2004, 44:136–141.CrossRefPubMedGoogle Scholar
  41. 41.
    Nappi G, Micieli G, Tassorelli C, et al.: Effectiveness of a piroxicam fast dissolving formulation sublingually administered in the symptomatic treatment of migraine without aura. Headache 1993, 33:296–300.CrossRefPubMedGoogle Scholar
  42. 42.
    Dib M, Massiou H, Weber M, et al.: Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 2002, 58:1660–1665.PubMedGoogle Scholar
  43. 43.
    Meredith JT, Wait S, Brewer KL: A prospective double-blind study of nasal sumatriptan versus ketorolac in migraine. Am J Emerg Med 2003, 21:173–175.CrossRefPubMedGoogle Scholar
  44. 44.
    Turkewitz LJ, Casaly JS, Dawson GA, et al.: Self-administration of parenteral ketorolac tromethamine for head pain. Headache 1992, 32:452–454.CrossRefPubMedGoogle Scholar
  45. 45.
    Klapper JA, Stanton JS: Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache 1991, 31:523–524.CrossRefPubMedGoogle Scholar
  46. 46.
    Silberstein SD, McCrory DC: Butalbital in the treatment of headache: History, pharmacology, and efficacy. Headache 2001, 41:953–967.CrossRefPubMedGoogle Scholar
  47. 47.
    Evans RW, Baskin SM: Why do migraineurs abuse butalbital-containing combination analgesics? Headache 2010, 50:1194–1197.CrossRefPubMedGoogle Scholar
  48. 48.
    Jakubowski M, Levy D, Goor-Aryeh I, et al.: Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005, 45:850–861.CrossRefPubMedGoogle Scholar
  49. 49.
    •• Bigal ME, Lipton RB: Excessive opioid use and the development of chronic migraine. Pain 2009, 142:179–182. CrossRefPubMedGoogle Scholar
  50. 50.
    Bigal ME, Serrano D, Buse D, AL ET: Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008, 48:1157–1168.CrossRefPubMedGoogle Scholar
  51. 51.
    Silberstein SD: Clinical practice guidelines. Cephalalgia 2005, 25:765–766.CrossRefPubMedGoogle Scholar
  52. 52.
    Saper JR, Lake AE, Hamel RL, et al.: Daily scheduled opioids for intractable head pain: Long-term observations of a treatment program. Neurology 2004, 62:1687–1694.PubMedGoogle Scholar
  53. 53.
    Saper JR, Lake AE, Bain PA, et al.: A practice guide for continuous opioid therapy for refractory daily headache: Patient selection, physician requirements, and treatment monitoring. Headache 2010, 50:1175–1193.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Park Nicollet Headache CenterMinneapolisUSA
  2. 2.The Headache Center, Department of Neurology, University of PittsburghPittsburghUSA

Personalised recommendations